SCHEMBL3135701

SCHEMBL3135701

CNC(=O)C(C)c1ccccc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
GRM7 Q14831 2/20 0.54
POLB P06746 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.50
ERCC1 P07992 1/20 0.49
ERCC4 Q92889 1/20 0.49
PTGS2 P35354 1/20 0.48
GPR88 Q9GZN0 1/20 0.48
ELOVL1 Q9BW60 2/20 0.47
KCNQ2 O43526 1/20 0.47
HSD17B10 Q99714 1/20 0.47
GAA P10253 1/20 0.47
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2055561 1.00 LMNA (0.55) LMNAGRM7POLBL3MBTL1ERCC1
SCHEMBL2055558 1.00 LMNA (0.55) LMNAGRM7POLBL3MBTL1ERCC1
Trifluoroacetic Acid SCHEMBL27622630 0.89 GRM7 (0.46) LMNAGRM7POLBL3MBTL1ERCC1
SCHEMBL7748974 0.83 POLB (0.66) LMNAPOLBL3MBTL1HSD17B10GAA
SCHEMBL17365594 0.83 POLB (0.66) LMNAPOLBL3MBTL1HSD17B10GAA
SCHEMBL4729281 0.83 HDAC3 (0.63) LMNAGRM7POLBL3MBTL1ERCC1
SCHEMBL7559906 0.83 HDAC3 (0.63) LMNAGRM7POLBL3MBTL1ERCC1
SCHEMBL10210457 0.82 TP53 (0.46) PTGS2
SCHEMBL2605850 0.81 MEN1 (0.47) LMNAGRM7POLBL3MBTL1ERCC1
SCHEMBL23453428 0.81 MAPT (0.57) HSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4240363-A1 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 Merck Sharp & Dohme LLC (US) 2023-09-13 EP disclosed
CN-116217414-A Preparation method of N-methyl-3-hydroxyamphetamine 山东新时代药业有限公司 2023-06-06 CN disclosed
US-20230130980-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS TECHFIELDS PHARMA CO., LTD. (CN) 2023-04-27 US disclosed
WO-2022098806-A1 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 MERCK SHARP & DOHME CORP. (US) 2022-05-12 WO disclosed
US-20180222921-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS PREMIER RESEARCH INTERNATIONAL, LLC 2018-08-09 US disclosed
US-9969751-B2 High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds TECHFIELDS PHARMA CO., LTD. (CN) 2018-05-15 US disclosed
EP-1937643-B1 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF SECOND GENOME INC (US) 2016-07-13 EP disclosed
EP-1933622-B1 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF SECOND GENOME INC (US) 2016-03-09 EP disclosed
WO-2016001789-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS FOR USE IN THE TREATMENT OF CANCER PFIZER INC. (US) 2016-01-07 WO disclosed
US-9006433-B2 Substituted pyrimidines MERCK SHARP & DOHME CORP. (US) 2015-04-14 US disclosed
US-20100040548-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS TECHFIELDS PHARMA CO., LTD (CN) 2010-02-18 US disclosed
CN-101627007-A Aminoamides as orexin antagonists HOFFMANN LA ROCHE 2010-01-13 CN disclosed
US-7488752-B2 nor-seco himbacine derivatives; thrombosis, anticoagulants, anticancer agents; antiinflammatory agents; anticholesterol agents; cardiovascular disorders; antiarrhythmia agents; antiischemic agents; strokes; antiarthritic agents SCHERING CORPORATION (US) 2009-02-10 US disclosed
EP-1457512-B1 Multi-branched polymer, process for producing the same, and applications thereof MITSUI CHEMICALS INC (JP) 2008-05-07 EP disclosed
WO-2007109160-A9 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF RENOVIS INC (US) 2007-11-15 WO disclosed
WO-2007109160-A2 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF RENOVIS, INC. (US) 2007-09-27 WO disclosed
WO-2007109192-A2 BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF RENOVIS, INC. (US) 2007-09-27 WO disclosed
US-20070225324-A1 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof SECOND GENOME, INC. 2007-09-27 US disclosed
US-20070225324-A1 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof SECOND GENOME, INC. 2007-09-27 US disclosed
CN-1649870-A 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases ACTELION PHARMACEUTICALS LTD (CH) 2005-08-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180222921-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS SLC7A1, VIP, HPGDS LMNA 4309/4885GRM7 3616/4885POLB 1882/4885
US-20230130980-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS SLC7A1, VIP, HPGDS LMNA 4309/4885GRM7 3616/4885POLB 1882/4885
US-20070225324-A1 Bicycloheteroaryl compounds as P2X7 modulators and uses thereof P2RX7, P2RX3, P2RX2 LMNA 1911/4885GRM7 198/4885POLB 3676/4885
US-20100040548-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS SLC7A1, VIP, HAMP LMNA 4231/4885GRM7 3670/4885POLB 1766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.